Salomez-Ihl Salomez-Ihl

Dr. Salomez-Ihl Salomez-Ihl


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 August 2024 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Open access
SSSalomez-Ihl Salomez-Ihl
Salomez-Ihl Salomez-Ihl
JGJ. Giai
J. Giai
MBM. Barbado
M. Barbado
APA. Paris
A. Paris
STS. Touati
S. Touati
JBJ. P. Brion
J. P. Brion
The coronavirus disease 2019 (COVID-19) pandemic, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has triggered a serious global health crisis, resulting in millions of reported deaths since its initial identification in China in November 2019. The global disparities in immunization access emphasize the urgent need for ongoing research into therapeutic interventions. This study focuses on the potential use of molecular dihydrogen (H2) inhalation as an adjunctive treatment for COVID-19. H2 therapy shows promise in inhibiting intracellular signaling pathways associated with inflammation, particularly when administered early in conjunction with nasal oxygen therapy. This phase I study, characterized by an open-label, prospective, monocentric, and single ascending-dose design, seeks to assess the safety and tolerability of the procedure in individuals with confirmed SARS-CoV-2 infection. Employing a 3 + 3 design, the study includes three exposure durations (target durations): 1 day (D1), 3 days (D2), and 6 days (D3). We concluded that the maximum tolerated duration is at least 3 days. Every patient showed clinical improvement and excellent tolerance to H2 therapy. To the best of our knowledge, this phase I clinical trial is the first to establish the safety of inhaling a mixture of H2 (3.6%) and N2 (96.4%) in hospitalized COVID-19 patients. The original device and method employed ensure the absence of explosion risk. The encouraging outcomes observed in the 12 patients included in the study justify further exploration through larger, controlled clinical trials. CLINICAL TRIALS: This study is registered with ClinicalTrials.gov as NCT04633980 .

Verified
Journal Article
Open access
PDF file
YGYoann GABOREAU
Yoann GABOREAU
AMAleksandra Milovancev
Aleksandra Milovancev
CRCarole Rolland
Carole Rolland
CEClaire Eychenne
Claire Eychenne
JAJean-Pierre Alcaraz
Jean-Pierre Alcaraz
JBJean-Luc Bosson
Jean-Luc Bosson
Background. Due to its antioxidant, anti-inflammatory, anti-apoptosis, and anti-fatigue properties, molecular hydrogen (H2) is potentially a novel therapeutic nutrient for patients with coronavirus acute disease 2019 (COVID-19). We determined the efficacy and safety profile of hydrogen-rich water (HRW) to reduce the risk of COVID-19 progression. Methods: We also conducted a phase 3, triple-blind, randomised, placebo-controlled trial to evaluate treatment with HRW initiated within 5 days after the onset of signs or symptoms in primary care patients with mild-to-moderate, laboratory-confirmed COVID-19. Participants were randomised to receive HRW or placebo twice daily for 21 days. The incidence of clinical worsening and adverse events were the primary endpoints. Results: A total of 675 participants were followed up to day 30. HRW was not superior to placebo in preventing clinical worsening at day 14: in H2 group, 46.1% in the H2 group, 43.5% in the placebo group, hazard ratio 1.09, 90% confidence interval [0.90–1.31]. One death was reported at day 30 in the H2 group and two in the placebo group at day 30. Adverse events were reported in 91 (27%) and 89 (26.2%) participants, respectively. Conclusions: HRW taken twice daily from the onset of COVID-19 symptoms for 21 days did not reduce clinical worsening.

12 September 2024 in Annales Pharmaceutiques Françaises
Verified
Journal Article
Closed access
SSSalomez-Ihl Salomez-Ihl
Salomez-Ihl Salomez-Ihl
CCClaire Chapuis
Claire Chapuis
PAPierre Albaladejo
Pierre Albaladejo
MPMarielle Picard
Marielle Picard
ABAline Baron
Aline Baron
PBPierrick Bedouch
Pierrick Bedouch

28 April 2026 in Respiratory Research
Verified
Journal Article
Open access
PDF file
Tyler W. LeBaronTyler W. LeBaron
Tyler W. LeBaron
KOKinji Ohno
Kinji Ohno
SSSalomez-Ihl Salomez-Ihl
Salomez-Ihl Salomez-Ihl
PCPhilippe Cinquin
Philippe Cinquin
FBFrancois Boucher
Francois Boucher
JKJohn Nagi Kheir
John Nagi Kheir
Molecular hydrogen (H2 gas) has emerged as a promising therapeutic agent with reported benefits across oxidative stress, inflammation, cardiovascular, and


7 August 2024 in European Journal of Anaesthesiology
Verified
Journal Article
Closed access
SSSalomez-Ihl Salomez-Ihl
Salomez-Ihl Salomez-Ihl
CCClaire Chapuis
Claire Chapuis
PBPierrick Bedouch
Pierrick Bedouch
PAPierre Albaladejo
Pierre Albaladejo
JPJulien Picard
Julien Picard